JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cohen, M. L.
Right arrow Articles by Schenck, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cohen, M. L.
Right arrow Articles by Schenck, K.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH

Vol. 290, Issue 3, 935-939, September 1999

5-Hydroxytryptamine1F Receptors Do Not Participate in Vasoconstriction: Lack of Vasoconstriction to LY344864, a Selective Serotonin1F Receptor Agonist in Rabbit Saphenous Vein

Marlene L. Cohen and Kathryn Schenck

Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana

Recently, several novel approaches to the treatment of migraine have been advanced, including selective 5-hydroxytryptamine (or serotonin) 1B/1D (5-HT1B/1D) receptor agonists such as sumatriptan and 5-HT1F receptor agonists such as LY344864. Many 5-HT1B/1D receptor agonists have been identified based on their ability to produce cerebral vascular contraction, whereas LY344864 was identified as an inhibitor of trigeminal nerve-mediated dural extravasation. In our study, several triptan derivatives were compared with LY344864 for their ability to contract the rabbit saphenous vein, a tissue used in the preclinical identification of sumatriptan-related agonists. Sumatriptan, zolmitriptan, rizatriptan, and naratriptan all contracted the rabbit saphenous vein from baseline tone, whereas LY344864 in concentrations up to 10-4 M did not contract the rabbit saphenous vein. Furthermore, vascular contractions to sumatriptan were markedly augmented in the presence of prostaglandin F2alpha (PGF2alpha ). However, even in the presence of PGF2alpha (3 × 10-7 M), LY344864 did not contract the rabbit saphenous vein in concentrations well in excess of its 5-HT1F receptor affinity (pKi = 8.2). Only when concentrations exceeded those likely to activate 5-HT1B and 5-HT1D receptors (>10-5 M) did modest contractile responses occur in the presence of PGF2alpha . Use of these serotonergic agonists revealed a significant correlation between the contractile potency in the rabbit saphenous vein and the affinities of these agonists at 5-HT1B and 5-HT1D receptors, although contractile agonist potencies were not quantitatively similar to 5-HT1B or 5-HT1D receptor affinities. In contrast, no significant correlation existed between the contractile potencies of these serotonergic agonists in the rabbit saphenous vein and their affinity at 5-HT1F receptors. These data support the contention that activation of 5-HT1F receptors will not result in vascular contractile effects.


0022-3565/99/2903-0935$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
A. Bhattacharya, K. W. Schenck, Y.-C. Xu, L. Nisenbaum, E. Galbreath, and M. L. Cohen
5-Hydroxytryptamine1B Receptor-Mediated Contraction of Rabbit Saphenous Vein and Basilar Artery: Role of Vascular Endothelium
J. Pharmacol. Exp. Ther., May 1, 2004; 309(2): 825 - 832.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
S. W. Watts
Serotonin-Induced Contraction in Mesenteric Resistance Arteries: Signaling and Changes in Deoxycorticosterone Acetate-Salt Hypertension
Hypertension, March 1, 2002; 39(3): 825 - 829.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
C. M. McKune and S. W. Watts
Characterization of the Serotonin Receptor Mediating Contraction in the Mouse Thoracic Aorta and Signal Pathway Coupling
J. Pharmacol. Exp. Ther., April 1, 2001; 297(1): 88 - 95.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics.